HIV

The Pharmacy Times® human immunodeficiency virus (HIV) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
During this study, no patient receiving TDF and FTC was admitted to intensive care or died.
[[thumbnail_alt_text]]
The FDA has approved cabenuva, which consists of rilpivirine and cabotegravir, for treating HIV-1 infection in adults. This therapy is the first once-monthly, long-acting injectable to be approved for the treatment of HIV.
[[thumbnail_alt_text]]
The study results showed that cabotegravir was 89% more effective than daily oral FTC/TDF for preexposure prophylaxis (PrEP).
[[thumbnail_alt_text]]
A recent study sought to investigate the attitudes of women with a history of injection—both medical and substance use—toward long-acting injectable HIV therapies.
[[thumbnail_alt_text]]
The right balance of stem cell dose, cell type, and timing of antiretroviral therapy (ART) could potentially lead to a spontaneous cure of HIV, according to the study authors.
[[thumbnail_alt_text]]
As patients with HIV are living longer, they are also being diagnosed with chronic conditions that have become increasingly common in recent decades, putting them at higher risk of COVID-19 hospitalization and death.
 
[[thumbnail_alt_text]]
At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.
[[thumbnail_alt_text]]
The FDA has approved Rukobia (fostemsavir) for the treatement of human immunodeficiency virus 1 (HIV-1) infection. 
[[thumbnail_alt_text]]
Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.
[[thumbnail_alt_text]]
Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
[[thumbnail_alt_text]]
Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
[[thumbnail_alt_text]]
The US Department of Health & Human Services released guidance at the beginning of the pandemic clarifying guidelines regarding best practices in HIV care.